Skip to main content Skip to footer
American Family Children's Hospital
Mark A. Ritter, MD, PhD close
Mark A. Ritter, MD, PhD

New Patients

Need help selecting a primary care doctor? Contact the Welcome Center for personal assistance.

For Referring Physicians

How to refer a patient

Mark A. Ritter, MD, PhD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Ritter specializes in treating patients with gastrointestinal and genitourinary cancers, including liver and pancreas, colon, stomach, bladder, prostate, testicular and kidney.



UW Carbone Cancer Center
(608) 263-8500 | (800) 323-8942 | Map
University Hospital
(608) 263-7502 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Hospital Affiliation(s)

University Hospital
UnityPoint Health - Meriter

UW School of Medicine and Public Health

Department of Human Oncology

Professional Certifications and Education

Board Certification Radiation Oncology
Residency Hospital of the University of Pennsylvania, Philadelphia, PA
Internship Hospital of the University of Pennsylvania, Philadelphia, PA
Medical School University of Miami Miller School of Medicine, Miami, FL

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

Dr. Ritter’s research involves the investigation of biology and technology-driven optimization of treatment for prostate cancer.

PubMed Articles
Pathmanathan AU van As NJ Kerkmeijer LGW Christodouleas J Lawton CAF Vesprini D van der Heide UA Frank SJ Nill S Oelfke U van Herk M Li XA Mittauer K Ritter M Choudhury A Tree AC Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? Int J Radiat Oncol Biol Phys . 2018 Feb 1;100(2):361-373
[PubMed ID: 29353654]
Harari PM Ritter MA van der Kogel AJ Obituary and Tribute to John "Jack" Francis Fowler, PhD, DSc (1925-2016). Int J Radiat Oncol Biol Phys . 2017 Apr 1;97(5):886-888
[PubMed ID: 28333004]
Brower JV Chen S Bassetti MF Yu M Harari PM Ritter MA Baschnagel AM Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys . 2016 Dec 1;96(5):985-993
[PubMed ID: 27869098]
Johnson SB Soulos PR Shafman TD Mantz CA Dosoretz AP Ross R Finkelstein SE Collins SP Suy S Brower JV Ritter MA King CR Kupelian PA Horwitz EM Pollack A Abramowitz MC Hallman MA Faria S Gross CP Yu JB Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol . 2016 Nov;121(2):294-298
[PubMed ID: 27890426]
Morris ZS Saha S Magnuson WJ Morris BA Borkenhagen JF Ching A Hirose G McMurry V Francis DM Harari PM Chappell R Tsuji S Ritter MA Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer . 2016 Aug 15;122(16):2487-95
[PubMed ID: 27203227]
Brower JV Forman JD Kupelian PA Petereit DG Gondi V Lawton CA Anger N Saha S Chappell R Ritter MA Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. Radiother Oncol . 2016 Jan;118(1):99-104
[PubMed ID: 26755165]
Yu J Hardcastle N Jeong K Bender ET Ritter MA Tomé WA On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration. Technol Cancer Res Treat . 2015 Feb;14(1):37-47
[PubMed ID: 24354754]
Jarrard DF Blute ML Jr Ritter MA Potential role for androgen-deprivation therapy and pelvic radiation therapy in node-positive postprostatectomy prostate cancer. J Clin Oncol . 2014 Dec 10;32(35):3926-9
[PubMed ID: 25332250]
Petereit DG Hahn LJ Kanekar S Boylan A Bentzen SM Ritter M Moser AR Prevalence of ATM Sequence Variants in Northern Plains American Indian Cancer Patients. Front Oncol . 2013;3:318
[PubMed ID: 24416720]
Verhoven B Yan Y Ritter M Khor LY Hammond E Jones C Amin M Bahary JP Zeitzer K Pollack A Ki-67 is an independent predictor of metastasis and cause-specific mortality for prostate cancer patients treated on Radiation Therapy Oncology Group (RTOG) 94-08. Int J Radiat Oncol Biol Phys . 2013 Jun 1;86(2):317-23
[PubMed ID: 23474109]
Babaian K Truong M Cetnar J Cross DS Shi F Ritter MA Jarrard DF Analysis of urological procedures in men who died from prostate cancer using a population-based approach. BJU Int . 2013 Mar;111(3 Pt B):E65-70
[PubMed ID: 23130676]
Fashoyin A Hartig G Schelman WR Ritter M Agni R Gopal DV Pfau PR Weiss JM Aggressive adenocarcinoma of the cervical esophagus: importance of a multidisciplinary approach. Case Rep Gastrointest Med . 2012;2012:826246
[PubMed ID: 23304576]
Adkison JB McHaffie DR Bentzen SM Patel RR Khuntia D Petereit DG Hong TS Tomé W Ritter MA Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer. Int J Radiat Oncol Biol Phys . 2012 Jan 1;82(1):184-90
[PubMed ID: 21163590]
Kruser TJ Jarrard DF Graf AK Hedican SP Paolone DR Wegenke JD Liu G Geye HM Ritter MA Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer . 2011 Jun 15;117(12):2629-36
[PubMed ID: 21656740]
Schubert LK Westerly DC Tomé WA Mehta MP Soisson ET Mackie TR Ritter MA Khuntia D Harari PM Paliwal BR A comprehensive assessment by tumor site of patient setup using daily MVCT imaging from more than 3,800 helical tomotherapy treatments. Int J Radiat Oncol Biol Phys . 2009 Mar 15;73(4):1260-9
[PubMed ID: 19251098]
Ritter M Forman J Kupelian P Lawton C Petereit D Hypofractionation for prostate cancer. Cancer J . 2009 Jan-Feb;15(1):1-6
[PubMed ID: 19197165]
Ritter M Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer. Semin Radiat Oncol . 2008 Oct;18(4):249-56
[PubMed ID: 18725112]
Hutson PR Oettel K Douglas J Ritter M Messing E Staab MJ Alberti D Horvath D Wilding G Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test. Cancer Chemother Pharmacol . 2008 Aug;62(3):373-7
[PubMed ID: 17922273]
Wong GW Palazzi-Churas KL Jarrard DF Paolone DR Graf AK Hedican SP Wegenke JD Ritter MA Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys . 2008 Feb 1;70(2):449-55
[PubMed ID: 17869014]
Ritter MA Prognostic and predictive markers in radiation therapy: focus on prostate cancer. Cancer Treat Res . 2008;139:97-114
[PubMed ID: 18236713]